A surge of consolidation, rising appetite for specialized manufacturing and a shift toward decentralized trials is reshaping Switzerland’s life sciences landscape. From peptide producers to organoid CROs, service providers are scaling and diversifying as global sponsors turn to Swiss hubs for…
Source: Biospace
This item was collected automatically from an official industry feed. Follow the source link for the complete announcement and primary documentation.